4H-吡咯并[2,3-d]恶唑-5-羧酸 | 1041421-52-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 4H-吡咯并[2,3-d]恶唑-5-羧酸
• 英文名称: 4H-pyrrolo[2,3-d]oxazole-5-carboxylic acid
• 英文别名: 4H-pyrrolo[2,3-d][1,3]oxazole-5-carboxylic acid
• CAS: 1041421-52-6
• 化学式: C₆H₄N₂O₃
• mdl: MFCD11501499
• 分子量: 152.109
• InChiKey: MIZFEOBWVJHCNL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  79.1
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  ethyl 4H-pyrrolo[2,3-d][1,3]oxazole-5-carboxylate 在 sodium hydroxide 作用下， 生成 4H-吡咯并[2,3-d]恶唑-5-羧酸
  参考文献：
  名称：

  The discovery of fused pyrrole carboxylic acids as novel, potent d-amino acid oxidase (DAO) inhibitors

  摘要：

  The 'NMDA hypofunction hypothesis of schizophrenia' can be tested in a number of ways. DAO is the enzyme primarily responsible for the metabolism of d-serine, a co-agonist for the NMDA receptor. We identified novel DAO inhibitors, in particular, acid 1, which demonstrated moderate potency for DAO in vitro and ex vivo, and raised plasma d-serine levels after dosing ip to rats. In parallel, analogues were prepared to survey the SARs of 1.

  DOI：

  10.1016/j.bmcl.2008.04.020

文献信息

• Fused heterocyclic inhibitors of D-amino acid oxidase
  申请人：Heffernan L. R. Michele

  公开号：US20080058395A1

  公开（公告）日：2008-03-06

  This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. Also provided are methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein Q is a member selected from O, S, CR 1 and N, X and Y are members independently selected from CR 2 , O, S, N and NR 3 .

  本发明提供了D-氨基酸氧化酶的新型抑制剂，以及包括该发明化合物的制药组合物。同时，还提供了治疗和预防神经系统疾病，如神经精神疾病和神经退行性疾病，以及疼痛、共济失调和惊厥的方法。该发明化合物具有以下一般结构：其中Q是从O、S、CR1和N中选择的成员，X和Y是独立选择自CR2、O、S、N和NR3的成员。
• The discovery of fused pyrrole carboxylic acids as novel, potent d-amino acid oxidase (DAO) inhibitors
  作者：Tim Sparey、Pravien Abeywickrema、Sarah Almond、Nick Brandon、Noel Byrne、Alister Campbell、Pete H. Hutson、Marlene Jacobson、Brian Jones、Sanjeev Munshi、Danette Pascarella、Andrew Pike、G. Sridhar Prasad、Nancy Sachs、Melanie Sakatis、Vinod Sardana、Shankar Venkatraman、Mary Beth Young

  DOI：10.1016/j.bmcl.2008.04.020

  日期：2008.6

  The 'NMDA hypofunction hypothesis of schizophrenia' can be tested in a number of ways. DAO is the enzyme primarily responsible for the metabolism of d-serine, a co-agonist for the NMDA receptor. We identified novel DAO inhibitors, in particular, acid 1, which demonstrated moderate potency for DAO in vitro and ex vivo, and raised plasma d-serine levels after dosing ip to rats. In parallel, analogues were prepared to survey the SARs of 1.